400602-55-3

Upstream product

• 824-98-6 m-methoxybenzyl chloride 
• 552-89-6 2-nitro-benzaldehyde 
• 271-58-9 anthranil 
• 13939-06-5 molybdenum hexacarbonyl 
• 1798-09-0 m-methoxyphenylacetic acid 
• 400602-54-2 o-nitro-α-(3-methoxyphenyl) cinnamic acid 
• 107801-68-3 3,4-dihydro-3-(3-methoxyphenyl)-2(1H)-quinolinone 

Downstream Products

• 400602-56-4 3-(3-hydroxyphenyl)-quinolin-2(1H)-one 
• 914077-77-3 C₁₅H₁₂N₂O₄S 
• 400602-57-5 [3-(2-oxo-1,2-dihydro-quinolin-3-yl)-phenoxy]-acetic acid methyl ester 

Relevant academic research and scientific papers

Palladium-catalyzed carbonylative synthesis of 3-arylquinolin-2(1H)-ones from benzyl chlorides and o-nitrobenzaldehydes

A palladium-catalyzed carbonylative cyclization of benzyl chlorides with o-nitrobenzaldehydes has been developed for the synthesis of 3-arylquinolin-2(1H)-ones. Mo(CO)6 played a dual role as both a CO surrogate and a reductant in this carbonylative transformation.

Palladium-catalyzed carbonylative cyclization of benzyl chlorides with anthranils for the synthesis of 3-arylquinolin-2(1: H)-ones

An efficient carbonylative procedure for the synthesis of 3-arylquinoin-2(1H)-ones has been established. Through a palladium-catalyzed aminocarbonylation of benzyl chlorides with anthranils, a variety of 3-arylquinoin-2(1H)-one products were obtained in moderate to excellent yields with good functional group tolerance. This journal is

Intramolecular amidation - An efficient synthesis of 3-aryl-2-quinolinones

To reveal the scope of the syntheses of 3-aryl-2-quinolinones from 2-nitro-α-phenylcinnamic acids, the isomerization of (E)-2-amino-α- phenylcinnamic acids was studied. The results showed that (E)-2-amino-α- phenylcinnamic acids were isomerized to its (Z)

KERATINOCYTE GROWTH FACTOR RECEPTOR - TYROSINE SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTATIS

Compounds and methods for treating, inhibiting, or delaying the onset of cancer in subject by administering a therapeutically effective amount of a keratinocyte growth facto receptor tyrosine kinase (KGFR TK) inhibitor to the subject in need of such treatment. Als provided are compounds and methods for the treating, inhibiting, or delaying the onset o metastasis in a subject with cancer by administering a therapeutically effective amount of KGFR TK inhibitor to the subject in need of such treatment.

Design and synthesis of Pfmrk inhibitors as potential antimalarial agents.

The synthesis and inhibitory activities of 10 potential inhibitors of Pfmrk, a Plasmodium falciparum cyclin-dependent protein kinase, are described. The most potent inhibitor is a 3-phenyl-quinolinone compound with an IC(50) value of 18 microM. It is the first compound reported to inhibit Pfmrk at the micro molar range.